Advanced Cell Technology Inc. - ACTC
 |
|
Latest Newsletter Editions Thu, Sep 21, 2006 @ 05:09 pm
Comments in the BLOG There was a new BLOG posting this week on HDY. For those who remember that special situation, the news looks reasonably promising. Monday's BLOG forecasting the break out of CPNE proved prophetic, and the stock is now holding onto the $1.40 level- a new multi month high. I believe...
Wed, Sep 6, 2006 @ 02:09 pm
Wake Me Up When September Ends as my memory rests but never forgets what I lost wake me up when september ends Greenday from the song Wake Me Up When September Ends The lyrics from Greenday's hit song are worth remembering this time of year. Why? - did you know September is historically the worst month...
Sun, Sep 3, 2006 @ 10:09 am
Advanced Cellular (OTC BB: ACTC): High Profile News Fuels Wild Roller Coaster Ride The last two weeks of August are generally the quietest of the year. Not so for ACTC, the subject of my last two editions. Today will make three in a row- unprecedented in the 8 year history of the OTC Journal. Prior...
Sat, Aug 26, 2006 @ 11:08 am
Advanced Cellular (OTC BB: ACTC) Capital Raise Resets the Bar There isn't much else to write about this weekend. ACTC was clearly the story of the week in an otherwise dull, listless, last week of summer. However, ACTC is providing all the fireworks we need for a little excitement. Earlier this past...
Thu, Aug 24, 2006 @ 06:08 am
ACTC: Biggest Percentage One Day Gain Ever in OTC Journal That move happened in conjunction with the publication of the NY Times article which you can read (by referring back to the link above). In light of the kinds of research going on at ACTC, this is the kind of event that could easily happen in...
Click Here For More Newsletters on ACTC | |
Latest Blog Entries |
Quote Data
|
|
Business Summary
Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human stem cell technology in the fields of regenerative medicine and stem cell therapy in the United States. The company offers RPE cells for the treatment of age-related disease of the eye, including macular degeneration; hemangioblast cells for the treatment of various blood and cardiac disorders; and dermal cells for the treatment of dermal damage, including burns, wound repair, and surgery. It also develops and commercializes products for use in treatment of an array of chronic degenerative diseases and in regenerative repair of acute disease, such as trauma, infarction, and burns. The company, formerly known as A.C.T. Holdings, Inc., was founded in 1994 and is headquartered in Alameda, California.
Disclosure
MarketByte LLC has been paid a fee of $30,000 and 250,000 warrants, exercisable at $2.54, by Advanced Cell Technology for coverage of the company.
Recent News Headlines
Fri, 17 May 2013 17:04:23 GMT
Thu, 16 May 2013 12:30:00 GMT
[Business Wire] - Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, today confirmed that the vision of a patient enrolled in a clinical investigation of the company’s retinal pigment epithelial cells derived from human embryonic stem cells has improved from 20/400 to 20/40 following treatment.
Thu, 16 May 2013 05:32:09 GMT
Thu, 16 May 2013 05:26:05 GMT
Wed, 15 May 2013 15:59:58 GMT
Fri, 10 May 2013 02:37:03 GMT
[at Seeking Alpha] - Advanced Cell Technology's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, 09 May 2013 20:00:00 GMT
[Business Wire] - Advanced Cell Technology, Inc. a leader in the field of regenerative medicine, announced today its first quarter financial results for the period ended March 31, 2013.
Thu, 09 May 2013 13:18:08 GMT
Mon, 06 May 2013 12:30:00 GMT
[Business Wire] - Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, announced today that it will release its first quarter financial results for the period ended March 31, 2013 after the market closes and hold an earnings call on Thursday, May 9th, 2013 at 4:30 p.m.
Mon, 06 May 2013 00:00:00 GMT
Wed, 01 May 2013 18:07:44 GMT
Wed, 01 May 2013 13:43:41 GMT
Wed, 01 May 2013 09:33:21 GMT
Fri, 26 Apr 2013 00:00:00 GMT
Tue, 23 Apr 2013 12:30:00 GMT
[Business Wire] - Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, today announced treatment of the first patient in the third dosage cohort, and seventh patient overall, in its European Phase I clinical trial for Stargardt’s macular dystrophy using retinal pigment epithelial cells derived from human embryonic stem cells .
Wed, 17 Apr 2013 12:36:00 GMT
Tue, 16 Apr 2013 19:54:44 GMT
[at noodls] - MARLBOROUGH, Mass. - April 16, 2013 - Advanced Cell Technology, Inc.("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced that Chairman and CEO Gary Rabin will ...
Tue, 16 Apr 2013 12:30:00 GMT
[Business Wire] - Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, today announced that Chairman and CEO Gary Rabin will present at the Alliance f
Mon, 15 Apr 2013 16:35:52 GMT
[at noodls] - ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt's Macular Dystrophy Patient Injected with 100,000 human embryonic stem cell-(hESC) derived Retinal Pigment Epithelial Cells MARLBOROUGH, ...
Mon, 15 Apr 2013 12:30:00 GMT
[Business Wire] - Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, today announced treatment of the first patient in patient cohort 2a, consisting of patients with better vision, in its U.S.